ALX Oncology Holdings Inc. (ALXO) Financial Statements (2024 and earlier)

Company Profile

Business Address 323 ALLERTON AVENUE
SOUTH SAN FRANCISCO, CA 94080
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2023
MRQ
12/31/2022
12/31/2021
12/31/2020
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments266,207363,667434,219
Cash and cash equivalents48,822363,667434,219
Short-term investments217,385  
Restricted cash and investments66  
Other undisclosed current assets4,6963,3521,773
Total current assets:270,969367,019435,992
Noncurrent Assets
Property, plant and equipment3,88989752
Long-term investments and receivables16,699  
Long-term investments16,699  
Other noncurrent assets14,93212,26710
Total noncurrent assets:35,52013,16462
TOTAL ASSETS:306,489380,183436,054
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities12,7908,1052,429
Employee-related liabilities3,2941,974
Accounts payable8,0733,7644
Accrued liabilities4,7171,047451
Debt 286429 
Due to related parties1,650  
Other liabilities   
Other undisclosed current liabilities13,5996,7613,775
Total current liabilities:28,32515,2956,204
Noncurrent Liabilities
Long-term debt and lease obligation9,389  
Long-term debt, excluding current maturities9,389  
Liabilities, other than long-term debt5,3111,8395
Other liabilities5,3111,8395
Total noncurrent liabilities:14,7001,8395
Total liabilities:43,02517,1346,209
Equity
Equity, attributable to parent263,464363,049429,845
Common stock414140
Additional paid in capital589,735564,993548,327
Accumulated other comprehensive loss(845)  
Accumulated deficit(325,467)(201,985)(118,522)
Total equity:263,464363,049429,845
TOTAL LIABILITIES AND EQUITY:306,489380,183436,054

Income Statement (P&L) ($ in thousands)

9/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
Revenues   1,182
Gross profit:   1,182
Operating expenses(127,436)(83,555)(44,845)
Operating loss:(127,436)(83,555)(43,663)
Nonoperating income (expense)(260)84(404)
Investment income, nonoperating   
Other nonoperating income (expense)(260)84(404)
Interest and debt expense(9)(13)(621)
Loss from continuing operations before equity method investments, income taxes:(127,705)(83,484)(44,688)
Other undisclosed income (loss) from continuing operations before income taxes4,287 (811)
Loss from continuing operations before income taxes:(123,418)(83,484)(45,499)
Income tax expense (benefit) (64)21(241)
Other undisclosed loss from continuing operations   
Loss from continuing operations:(123,482)(83,463)(45,740)
Loss before gain (loss) on sale of properties:(83,463)(45,740)
Other undisclosed net loss   
Net loss attributable to parent:(123,482)(83,463)(45,740)
Preferred stock dividends and other adjustments   (5,202)
Net loss available to common stockholders, diluted:(123,482)(83,463)(50,942)

Comprehensive Income ($ in thousands)

9/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
Net loss:(123,482)(83,463)(45,740)
Comprehensive loss:(123,482)(83,463)(45,740)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(845)  
Comprehensive loss, net of tax, attributable to parent:(124,327)(83,463)(45,740)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: